The specificity and sensitivity of two commercial enzyme linked immunosorbent assays (ELISAs), Diamedix (Miami, Florida) 
were also positive in both ELISA systems (only five of the seven patients were assayed by the Lipogen ELISA system). Two sera were tested in this system. Test procedures were the same as those described for dsDNA, except that the sera were diluted 1 in 100 for Sm, SSA/Ro, and SSB/La and for Lipogen RNP. The dilution for Diamedix RNP was 1 in 400.
Results and Discussion Sera from 53 patients with various connective tissue disorders were first examined for the presence of antibodies to nuclear antigens (ANA). Of the 53 patients, 42 were ANA positive with titres ranging from 1/20 to 1/20, 480, and 11 were ANA negative (table 1). Both the ANA positive and ANA negative sera were then examined for the presence of antibodies to double stranded DNA (dsDNA), Sm, RNP, SSA/Ro and SSB/La antigens. Antibodies to dsDNA, as well as ANA positivity, were used for assessing cross reactivity. Antibody reactivity was determined by different assay systems routinely used in our laboratory. The ELISA was used to determine antibodies to dsDNA, the haemagglutination assay was used for determination of anti-Sm and anti-RNP antibodies and anti-SSA/Ro, and anti-SSB/La antibodies were assayed by immunodiffusion.
Among the 42 ANA positive patients, 22 had antibodies to dsDNA, (table 1) seven had antibodies to Sm, and 10 were positive for RNP. SSA/Ro and SSB/La antibodies were found in 11 and six patients, respectively. Lines of partial identity were also identified in nine patients for SSA/Ro and in two for SSB/La antigens. The ANA negative sera (data not shown) were negative for the above antigens except for one patient who was ANA negative but who showed reactivity against SSA/Ro antigen (data not shown 
